Umsatz von Novo Nordisks Diabetes -Medikamenten, einschließlich Ozempic Slow stark: Das dänische Unternehmen, um Kosten zu senken und Entlassungen nach dem Wettbewerb durch Mounjaro und den Nachahmermarkt zu berücksichtigen
https://www.theguardian.com/business/2025/aug/06/sales-of-novo-nordisk-diabetes-drugs-including-ozempic-slow-sharply
Von Ok_Plankton_5714
6 Kommentare
NOVO has in the past 6 months delivered a 55 billion kroner profit (Danish record).
It is still making money. A lot of money. It is just the expectations and predicted growth that did not meet reality.
If they get the prices down they can ramp up volume. The prices are ridiculous for it. There is also approvals processes in motion from insurance companies to get it approved the same way statins are.
It’s a really competitive market for obesity meds
Patent dies in a year. Generic Ozempic for all.
Patent for Ozempic expires next year.
Mounjaro is better for most purposes.
It’s a tough spot for them.
A competitor?
I’ll ready the longboats.